Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

How to Buy Coronavirus Vaccine Stocks in 2021

By Adria Cimino - Dec 8, 2020 at 8:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Are the big gains over? No. But the game is changing.

Coronavirus vaccine stocks might have been investors' biggest bet this year. And, in general, it paid off. As companies brought investigational vaccines through clinical trials and released encouraging data, shares soared. This was particularly true of clinical stage biotech companies.

Today, as 13 vaccine programs approach the finish line and 2020 draws to a close, we might wonder: Will this investment theme continue in 2021? The answer is "yes." And will it be as profitable for investors? The answer to this is also "yes." But the game will be a bit different. Let's take a closer look at what to consider when buying coronavirus vaccine stocks in the coming year.

A doctor holds out his hand in the air and the number/year "2021" floats above it.

Image source: Getty Images.

In 2020, risk was high

First, a glance at what coronavirus vaccine investing was like this year. When we started talking about these stocks, risk was high. Companies' vaccine candidates were in preclinical studies, or at most, in phase 1 trials.

Moderna ( MRNA -11.87% ), which recently requested Emergency Use Authorization (EUA), in March became the first to launch a coronavirus vaccine trial in humans. Buying shares of Moderna back then meant investing before we had any inkling of whether its vaccine candidate would be safe and efficacious. In return for taking that big risk, investors reaped great rewards.

Also, coronavirus vaccine stocks have brought in rapid gains. Moderna stock has jumped 631% this year, and biotech rival Novavax ( NVAX -7.66% ) has surged more than 3,000%, for example. As a result, the market value of both companies also has soared.

MRNA Chart

MRNA data by YCharts

Now, let's see what's changed since the debut of this investment theme. It's as simple as this: risk, returns, and a focus on revenue.

Authorization doesn't equal approval

Let's start with risk. Of course, risk still remains. The U.S. Food and Drug Administration hasn't yet granted EUAs to vaccine makers. If and when it does, authorization doesn't equal approval. The FDA will continue evaluating data as it considers whether to grant full approval. Failure can happen even at this stage.

Still, companies that have brought a vaccine candidate into phase 3 trials carry less risk than those with earlier stage programs. That's because, by late-stage studies, we know more about the candidate's safety and efficacy. And that helps us gauge whether we're backing a strong player. So, today, investing in coronavirus vaccine stocks has become less risky.

As for returns, I'm optimistic there are more gains to come. But the pace will slow. Companies that have brought programs into late-stage trials -- or those who will win EUAs -- no longer are risky bets on near-term share performance. They are becoming long-term bets.

This brings me to my next point: Revenue. With vaccines closer to market, the next share price catalyst for their developers is vaccine revenue. If investors like what they see, shares will climb. And if revenue continues to grow, share gains are likely to last.

How should you invest?

So, considering these elements, how should you invest in coronavirus vaccine stocks now and into 2021?

This year, companies such as Moderna and Novavax were best left to aggressive investors. These biotechs don't have other products on the market. So, they're more dependent on an eventual coronavirus vaccine for revenue than big pharma rival Pfizer ( PFE 1.77% ), for instance.

Now, with Moderna's vaccine candidate under FDA review, the more cautious investor may take a second look. That investor might even consider a small position in the stock today -- or wait for a potential EUA and then bet on Moderna's future revenue. Novavax is worth a second look too. The company plans to report phase 3 data early in the first quarter.

So, for the cautious investor, the best way to invest in coronavirus vaccine stocks in 2021 is to focus on companies that are almost sure to soon generate revenue from the potential product. That doesn't mean the more aggressive investor should leave vaccine stocks behind, though. Some companies with exciting earlier stage programs are ultra-risky -- but offer potential for steep share gains.

This year, investing in coronavirus vaccine stocks was all about risk. It brought wealth to many but wasn't the right fit for a cautious, long-term investor. What's most exciting about coronavirus vaccine investing in 2021 is that the theme is broadening, making room for everyone -- regardless of investment style.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$310.61 (-11.87%) $-41.82
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$54.68 (1.77%) $0.95
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$192.65 (-7.66%) $-15.98

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.